* Voyager Therapeutics Inc is expected to show a rise in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2024

* The Lexington Massachusetts-based company is expected to report a 157.7% increase in revenue to $11.891 million from $4.61 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Voyager Therapeutics Inc is for a loss of 45 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Voyager Therapeutics Inc is 18.00​, above​ its last closing price of $7.00. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.41 -0.41 -0.18 Beat 56

Mar. 31 2024 -0.43 -0.44 -0.20 Beat 54.5

Dec. 31 2023 -0.16 -0.29 1.25 Beat 533.2​

Sep. 30 2023 -0.57 -0.58 -0.59 Missed -1.5

​​Jun. -0.57 -0.57 -0.51 Beat 10.3

30 2023

Mar. 31 2023 1.00 0.77 2.94 Beat 281​

Dec. 31 2022 -0.54 -0.55 -0.61 Missed -11.5

Sep. 30 2022 -0.31 -0.32 0.45 Beat 241.9

This summary was machine generated November 2 at 03:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)